ARCH Venture Partners
ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Business Model:
Revenue: $90M
Employees: 11-50
Rankings
Detailed ARCH Venture Partners Information
Geographic Data
Address: 8725 W Higgins Rd
City: Chicago
State: IL
Zip: 60631
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$9B
Social
Linkedin
Crunchbase
Metrics
1,629,290Website Global Rank
14,535Website Monthly Traffic
Twitter Followers
Description
ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venture funds totaling over $3 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.
Contact Phone:
+17733806600
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 5/2011 | Fate Therapeutics | Series B | 36M |
| 2/2020 | Volastra Therapeutics | Seed | 12M |
| 6/2015 | Aledade | Series B | 30M |
| 6/2015 | Twist Bioscience | Series C | 37M |
| 7/2016 | Sienna Biopharmaceuticals | Series A | 12M |
| 4/2016 | Sienna Biopharmaceuticals | Series A | 34M |
| 8/2010 | Kilimanjaro Energy | Series A | 2.3M |
| 10/2018 | Lyell Immunopharma | Series A | - |
| 5/2021 | Interline Therapeutics | Series A | 59.5M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 5/2015 | Denali Therapeutics | Series A | 217M |
| 5/2019 | Locanabio | Series A | 55M |
| 4/2022 | Be Biopharma | Series B | 0 |
| 8/2022 | Sironax | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 8/2018 | Karuna Therapeutics | Series A | 0 |
| 5/2000 | Alfalight | Series A | 6.1M |
| 3/2016 | Quanterix | Series D | 46M |
| 9/2003 | INFICON | Post-IPO Equity | 15M |
| 6/2018 | Biopalette | Seed Round | 5.2M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 10/2013 | Genuity Science | Series A | 15M |
| 9/2011 | Siluria Technologies | Series B | 20M |
| 7/2009 | Limerick BioPharma | Series C | 15M |
| 2/2000 | Teach.com | Venture Round | 6M |
| 8/1999 | Teach.com | Venture Round | 4.6M |
| 11/2015 | Codiak Biosciences | Series A | 31M |
| 6/2008 | Limerick BioPharma | Venture Round | 15.2M |
| 1/2021 | Encodia | Series C | 75M |
| 12/2016 | ApoGen Biotechnologies | Series A | 7M |
| 1/2015 | Hua Medicine | Series B | 0 |
| 10/2016 | Genomics Medicine Ireland | Series A | 40M |
| 11/2020 | Resilience | Series B | 0 |
| 1/2021 | Altos Labs | Series A | 3B |
| 3/2021 | OncoResponse | Series C | 0 |
| 1/2023 | Akamis Bio | Debt Financing | 0 |
| 12/2022 | Protillion Biosciences | Series A | 0 |
| 5/1995 | New Era of Networks | Series A | 2M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 2/2002 | SilverStorm Technologies | Venture Round | 0 |
| 1/2016 | Grail | Series A | 100M |
| 4/2021 | Volastra Therapeutics | Seed | 32M |
| 9/2018 | KSQ Therapeutics | Series C | 80M |
| 5/2002 | Impinj | Series F | 14M |
| 7/2018 | AgBiome | Series C | 0 |
| 12/2002 | Idun Pharmaceuticals | Series A | 22.8M |
| 9/2004 | Nura | Series A | 9.5M |
| 8/2021 | Recuro Health | Series A | 0 |
| 7/2021 | Slingshot Biosciences | Series A | 0 |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 10/2020 | Walden Biosciences | Series A | 51M |
| 12/2000 | Alfalight | Series B | 28M |
| 9/2004 | Vascular Architects | Series E | 0 |
| 3/2021 | Interline Therapeutics | Seed Round | 32.5M |
| 12/2002 | Ceptyr | Venture Round | 20M |
| 7/2008 | Agios | Series A | 33M |
| 7/2018 | Nohla Therapeutics | Series B | 11M |
| 6/2017 | Arbor Biotechnologies | Series A | 15.6M |
| 6/2019 | Ultivue | Series C | 22M |
| 6/2022 | Vizgen | Series C | 0 |
| 6/2020 | Verve Therapeutics | Series A | 63M |
| 5/2019 | Verve Therapeutics | Series A | 58.5M |
| 10/2016 | Carrick Therapeutics | Series A | 95M |
| 11/2002 | NexCura | Series C | 4M |
| 1/2019 | Vir Biotechnology | Series B | 327.6M |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 1/2021 | Cytrellis Biosystems | Series C | 50M |
| 3/2015 | Kura Oncology | Private Equity Round | 60M |
| 6/2018 | Cytrellis Biosystems | Series B | 0 |
| 8/2010 | Ciespace | Series A | 5M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 12/2013 | Juno Therapeutics | Series A | 120M |
| 10/2017 | KSQ Therapeutics | Series B | 76M |
| 8/2002 | Ahura Scientific | Series A | 12.5M |
| 8/2015 | Agrivida | Series D | 10.7M |
| 7/2012 | Chiasma | Series D | 38.5M |
| 1/2012 | Semprius | Venture Round | 7.5M |
| 5/2003 | Fast Track | Series D | 0 |
| 11/2017 | AnchorDx | Series B | 28M |
| 11/2007 | BIND Therapeutics | Series B | 16M |
| 9/2015 | Just - Evotec Biologics | Series A | 15M |
| 7/2014 | Faraday Pharmaceuticals | Series A | - |
| 5/2004 | Ensemble Therapeutics | Series A | 15M |
| 9/2000 | Impinj | Series A | 15M |
| 1/1992 | GenVec | Venture Round | - |
| 7/2019 | One BioMed | Series A | 5M |
| 2/2015 | Cytrellis Biosystems | Series A | 7.1M |
| 1/1994 | Eichrom Technologies | Venture Round | - |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 1/2009 | Qwell Pharmaceuticals | Series A | 7M |
| 4/1998 | Apropos Technology | Series C | 16M |
| 1/2002 | NeurogesX | Series B | 22.9M |
| 2/2023 | IngredientWerks | Seed Round | - |
| 12/2021 | ONI | Series B | 75M |
| 4/2021 | Ultivue | Series D | 50M |
| 9/2012 | Adesto Technologies | Series D | 14M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 10/2013 | Boreal Genomics | Series C | 0 |
| 7/2000 | LightCross, Inc. | Series A | 11.3M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 11/2009 | Receptos | Series A | 25M |
| 6/1996 | New Era of Networks | Series C | 7.5M |
| 10/2001 | Nanosys | Seed Round | 1.7M |
| 3/2007 | Surface Logix | Series D | 19.9M |
| 9/2008 | Sapphire Energy | Venture Round | 35M |
| 5/2018 | LunaDNA | Venture Round | 0 |
| 9/2010 | Sorbent Therapeutics | Series B | 0 |
| 7/2015 | Arivale | Series B | 36M |
| 8/2005 | Univa | Series A | 8M |
| 12/2013 | Bellerophon Therapeutics | Series A | 0 |
| 9/2005 | KOTURA | Series B | 13M |
| 8/2007 | Accelerator Corp. | Series C | 22.5M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 1/1989 | Nanophase Technologies | Venture Round | - |
| 5/2009 | Lycera | Series A | 0 |
| 12/2011 | Permeon Biologics | Venture Round | 2.5M |
| 2/2008 | MediaPhy | Series A | 7M |
| 11/2019 | EGenesis | Series B | 0 |
| 7/2012 | Impinj | Debt | 21M |
| 7/2003 | Alnylam Pharmaceuticals | Private Equity Round | 24.6M |
| 4/2017 | Sienna Biopharmaceuticals | Series B | 0 |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 3/2017 | Grail | Series B | 0 |
| 10/2013 | SAGE Therapeutics | Series B | 20M |
| 6/2000 | NeurogesX | Series A | 8.4M |
| 2/2021 | Excision BioTherapeutics | Series A | - |
| 12/2001 | R2 Technology | Venture Round | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 2/2008 | KOTURA | Series C | 0 |
| 5/2016 | OncoResponse | Series A | 0 |
| 7/2019 | Agrivida | Venture Round | 0 |
| 8/2017 | Hangzhou Just Biotherapeutics (Just China) | Series B | 59.6M |
| 2/2005 | Cambrios Technologies | Series B | 12M |
| 4/2007 | Shocking Technologies | Series A | 7M |
| 1/2018 | Gossamer Bio | Series A | 100M |
| 11/2016 | Nohla | Series A | 43.5M |
| 9/1999 | NexCura | Series A | 6M |
| 6/2004 | KOTURA | Series A | 11M |
| 12/1999 | ProjectGuides.com | Series A | - |
| 7/2018 | Omniome | Series B | 0 |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 8/2004 | Cambrios Technologies | Series A | 1.8M |
| 4/2007 | Cambrios Technologies | Series C | 18.5M |
| 11/2009 | Cambrios Technologies | Series D | 14.5M |
| 3/2004 | Artificial Muscle Inc. | Series A | 3.3M |
| 2/2014 | Twist Bioscience | Series A | 9.1M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 2/2023 | Slingshot Biosciences | Series A | 0 |
| 12/2020 | Locanabio | Series B | 0 |
| 3/2020 | Cero Therapeutics | Series A | 0 |
| 10/2015 | Aira Tech Corp. | Seed Round | 790k |
| 4/2021 | Vizgen | Series B | 0 |
| 5/2018 | Beam Therapeutics | Series A | 87M |
| 5/2008 | Univa | Series B | 0 |
| 6/2020 | JW Therapeutics | Series B | 0 |
| 1/2011 | Univa | Venture Round | 0 |
| 4/2001 | Fast Track | Series C | 0 |
| 8/1999 | Ceptyr | Venture Round | 11.5M |
| 9/2000 | Extreme Devices | Venture Round | 0 |
| 10/1999 | Intelligent Reasoning Systems | Venture Round | 7M |
| 10/2009 | Innovalight | Venture Round | 0 |
| 1/2005 | Ahura Scientific | Series B | 10M |
| 8/2011 | Shocking Technologies | Series C | 0 |
| 1/2002 | AmberWave | Series B | 25M |
| 6/2007 | Artificial Muscle Inc. | Series B | 20M |
| 2/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 8/2010 | Crystal IS | Venture Round | 4M |
| 11/2021 | Singleron Biotechnologies | Series B | 0 |
| 6/2009 | Semprius | Series B | 0 |
| 1/2005 | SilverStorm Technologies | Series A | 1.2M |
| 4/2020 | Erasca | Series B | 0 |
| 7/2016 | Hangzhou Just Biotherapeutics (Just China) | Series A | 14M |
| 8/2011 | Oncofactor | Series A | 2.1M |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 11/2017 | ImmusanT | Series C | 40M |
| 3/2004 | Reef Point Systems | Series D | 18M |
| 5/2021 | HiberCell | Series B | 0 |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 3/2006 | Theraclone Sciences | Series A | 0 |
| 5/2019 | LunaDNA | Venture Round | 4.6M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 12/2005 | NeurogesX | Series D | 20M |
| 4/2013 | Syros Pharmaceuticals | Series A | 30M |
| 9/2015 | Faraday Pharmaceuticals | Series A | 30M |
| 1/2021 | EQRx | Series B | 500M |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 1/2015 | UNITY Biotechnology | Series A | 2.3M |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 4/2012 | Sapphire Energy | Series C | 0 |
| 4/2005 | Ikaria | Series A | 10M |
| 10/2016 | UNITY Biotechnology | Series B | 116M |
| 3/2017 | Aledade | Series B | 40.2M |
| 9/1995 | New Era of Networks | Series B | 1.9M |
| 3/2012 | Receptos | Venture Round | 30M |
| 11/2002 | Surface Logix | Series C | 25M |
| 11/2005 | Nanosys | Series C | 0 |
| 3/2018 | UNITY Biotechnology | Series C | 55M |
| 8/2017 | UNITY Biotechnology | Series B | 35M |
| 5/2008 | Sapphire Energy | Series B | 50M |
| 3/2017 | EGenesis | Series A | 0 |
| 3/2007 | Ahura Scientific | Series B | 0 |
| 8/2003 | Xtera | Venture Round | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 6/2012 | Cooledge Lighting | Series A | 3.1M |
| 5/2012 | Newvem | Venture Round | 4M |
| 1/2011 | Acylin Therapeutics | Series A | 4.4M |
| 2/2010 | Shocking Technologies | Series B | 0 |
| 5/2020 | Mindstrong | Series C | 100M |
| 9/2022 | Orbital Therapeutics | Seed Round | - |
| 6/2021 | ImmuneID | Series A | 0 |
| 1/2007 | VBI Vaccines | Series A | 35.7M |
| 1/2018 | Scholar Rock | Series C | 47M |
| 1/2017 | Vir Biotechnology | Venture Round | 150M |
| 5/2004 | Ensemble Discovery | Series A | 15M |
| 11/2007 | Ensemble Discovery | Series B | 15M |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 2/2000 | Reef Point Systems | Venture Round | 22M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 1/2018 | Ultivue | Series B | 20M |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 4/2013 | Sorbent Therapeutics | Venture Round | 2.5M |
| 8/2022 | Vilya | Series A | 50M |
| 11/2021 | Generate Biomedicines | Series B | 0 |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 4/2023 | Recuro Health | Series B | 0 |
| 3/2023 | Rapport Therapeutics | Series A | 0 |
| 3/2016 | Aira | Series A | 2.5M |
| 8/2008 | Quanterix | Series A | 15M |
| 7/2006 | AmberWave | Series E | 0 |
| 1/2003 | Vascular Architects | Series D | 0 |
| 3/2022 | Recuro Health | Convertible Note | - |
| 12/2022 | SonoThera | Series A | 0 |
| 1/2021 | LifeMine Therapeutics | Series B | 0 |
| 6/2020 | bit.bio | Series A | 41.5M |
| 6/2017 | Mindstrong | Series A | 14M |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 6/2018 | Mindstrong | Series B | 15M |
| 11/2022 | Human Immunology Biosciences | Series A | 0 |
| 4/2010 | Achaogen | Series C | 56M |
| 6/2006 | Nitronex | Venture Round | 21.8M |
| 3/2019 | Erasca | Series A | 0 |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 10/2013 | NextCODE Health | Series A | 15M |
| 4/2015 | Movidius | Series E | 0 |
| 2/2002 | INFICON | Post-IPO Equity | 0 |
| 9/2018 | OncoResponse | Series B | 40M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 11/2012 | Nanosys | Series E | 15M |
| 2/2015 | Chiasma | Series E | 70M |
| 7/2012 | Cambrios Technologies | Venture Round | 3.9M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 8/2006 | Magen BioSciences | Series A | 15.4M |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 11/2022 | hC Bioscience | Series A | 0 |
| 9/2020 | Dewpoint Therapeutics | Series B | 0 |
| 11/2006 | Chiasma | Series C | 44M |
| 6/2004 | AmberWave | Series D | 21M |
| 11/2001 | AmberWave | Venture Round | - |
| 8/2009 | Shocking Technologies | Series B | 0 |
| 8/2014 | Juno Therapeutics | Series B | 134M |
| 10/2018 | Glympse Bio | Series A | 0 |
| 1/2016 | Codiak Biosciences | Series B | 61M |
| 7/2015 | Voxel8 | Series A | 12M |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 3/2022 | Nutcracker Therapeutics | Series C | 167M |
| 9/2020 | Nutcracker Therapeutics | Series B | 60M |
| 12/2020 | SciNeuro | Series A | 100M |
| 9/2014 | Scholar Rock | Series A | 20M |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 1/2010 | Innovalight | Series D | 0 |
| 5/2006 | Innovalight | Series B | 0 |
| 10/2019 | Prime Medicine | Series A | 115M |
| 4/2000 | eCustomers.com | Series B | 18M |
| 3/2007 | Ikaria | Series B | 280M |
| 7/2011 | Adesto Technologies | Series C | 17.4M |
| 8/2015 | AgBiome | Series B | 0 |
| 10/2016 | BlackThorn Therapeutics | Series A | 40M |
| 9/2012 | 908 Devices | Series A | 8.1M |
| 11/2003 | Medvantx | Series C | 5M |
| 4/1999 | eCustomers.com | Seed Round | - |
| 9/2020 | Biopalette | Series A | 9.5M |
| 2/2002 | Accumedia | Series C | 2M |
| 6/2002 | Xenoport | Series B | 43.9M |
| 4/2000 | ProjectGuides.com | Series B | 6.3M |
| 12/2019 | Epirium Bio | Series A | 0 |
| 9/2019 | Faraday Pharmaceuticals | Series B | 25M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 1/2000 | ePolicy | Series A | 14M |
| 4/2019 | Insitro | Series A | 100M |
| 7/2004 | Impinj | Series C | 22M |
| 3/2022 | LifeMine Therapeutics | Series C | 0 |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 5/2015 | 908 Devices | Series C | 11.6M |
| 8/2022 | Homeward | Series B | 0 |
| 6/2018 | Hangzhou Just Biotherapeutics (Just China) | Series B | 0 |
| 12/2002 | Alfalight | Series C | 15M |
| 6/2006 | VLST Corporation | Series B | 55M |
| 1/2019 | Transcenta | Venture Round | - |
| 1/2020 | EQRx | Series A | 200M |
| 1/2013 | Siluria Technologies | Series C | 2.9M |
| 5/2017 | Aira Tech Corp. | Series B | 12M |
| 4/2013 | AgBiome | Series A | 17.5M |
| 1/2020 | Vizgen | Series A | 14M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 2/2002 | Nanosys | Series A | 15M |
| 10/2006 | Aveso | Series B | 6.3M |
| 2/2004 | NeurogesX | Series C | 35M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 4/2013 | TRELYS | Seed Round | 2.5M |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 10/2007 | Innovalight | Series C | 0 |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 5/2018 | Brii Biosciences | Venture Round | 260M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 10/2005 | Surface Logix | Venture Round | 32M |
| 3/2009 | Surface Logix | Series E | 15M |
| 5/2018 | CStone Pharmaceuticals | Series B | 260M |
| 7/2018 | Qihan Biotech | Series A | 7.8M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 4/2016 | Hua Medicine | Series C | 0 |
| 1/2019 | Geneception | Series A | - |
| 7/2012 | Siluria Technologies | Series C | 30M |
| 11/2012 | Quanterix | Series C | 0 |
| 1/2020 | Omniome | Series C | 60M |
| 8/2007 | Xtera | Venture Round | 52M |
| 6/2018 | Metacrine | Series C | 65M |
| 10/2019 | Voxel8 | Series B | - |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 1/2020 | Transcenta | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 11/2011 | Agios | Series C | 78M |
| 9/2022 | Elephas | Series B | 41.5M |
| 3/2014 | SAGE Therapeutics | Series C | 38M |
| 2/2019 | HiberCell | Series A | 60.8M |
| 1/2000 | Illumina | Venture Round | 0 |
| 2/2007 | Omeros | Series E | 0 |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 7/2007 | Semprius | Series A | 4.1M |
| 6/2011 | Semprius | Series C | 20M |
| 6/2010 | Adesto Technologies | Venture Round | 3.5M |
| 5/2008 | Adesto Technologies | Series A | 11.5M |
| 8/2006 | Crystal IS | Series B | 10.6M |
| 11/2009 | Fate Therapeutics | Series B | 30M |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 10/2007 | Allozyne | Series B | 30M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 8/2015 | Metacrine | Series A | 36M |
| 11/2014 | AgBiome | Venture Round | 0 |
| 8/2002 | Midstream Technologies | Series C | 26M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 3/2001 | Midstream Technologies | Series B | 16M |
| 6/2015 | Pulmatrix | Post-IPO Equity | 10M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 3/2013 | Receptos | Series B | 30M |
| 3/2021 | EGenesis | Series C | 0 |
| 1/2016 | Scholar Rock | Series B | 36M |
| 12/2005 | Impinj | Series D | 26.5M |
| 11/2007 | Fate Therapeutics | Series A | 12M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 6/2010 | BIND Therapeutics | Series C | 12.4M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 10/2014 | Syros Pharmaceuticals | Series B | 53M |
| 2/2022 | Dewpoint Therapeutics | Series C | 0 |
| 5/2019 | LunaPBC | Venture Round | 4.6M |
| 5/2005 | Medvantx | Series D | 10.5M |
| 2/2022 | hC Bioscience | Series A | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 1/2023 | Paradigm | Series A | 0 |
| 8/2015 | PRIME Coalition | Venture Round | - |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 10/2015 | Pioneer Square Labs | Series A | 0 |
| 4/2021 | Jaguar Gene Therapy | Series B | 0 |
| 2/2023 | Aera Therapeutics | Series A | - |
| 1/2016 | Lodo Therapeutics | Series A | 0 |
| 9/2022 | Pretzel Therapeutics | Series A | 0 |
| 4/2021 | Treeline Biosciences | Series A | - |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 9/2011 | Hua Medicine | Series A | 50M |
| 3/2018 | Hua Medicine | Series D | 0 |
| 1/2019 | Sana Biotechnology | Seed Round | - |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 10/2018 | Nebula Genomics | Series A | 0 |
| 4/2000 | Nimble Technology | Series B | 16M |
| 5/2000 | Appliant.com | Venture Round | 20M |
| 3/2007 | Impinj | Series E | 19M |
| 10/2010 | Siluria Technologies | Series A | 13.3M |
| 9/2016 | Agrivida | Series E | 20.4M |
| 2/2021 | ImmuneID | Venture Round | 17M |
| 3/2017 | 908 Devices | Series D | 20M |
| 7/2021 | Prime Medicine | Series B | 200M |
| 5/2016 | Homology Medicines | Series A | 43.5M |
| 5/2014 | Twist Bioscience | Series B | 26M |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2020 | Singleron Biotechnologies | Series A | 30M |
| 9/2015 | Hangzhou Just Biotherapeutics (Just China) | Series A | 15M |
| 7/2016 | Just - Evotec Biologics | Series A | 14M |
| 4/2020 | ROME Therapeutics | Series A | 0 |
| 2/2023 | Aera Therapeutics | Series B | 0 |
| 9/2022 | Rippl Care | Seed Round | 32M |
| 12/2022 | Carrick Therapeutics | Series C | 0 |
| 6/2020 | Sana Biotechnology | Series A | 700M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 3/2021 | Insitro | Series C | 400M |
| 11/2022 | FogPharma | Series D | 0 |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 3/2023 | Volastra Therapeutics | Series A | 0 |
| 8/2016 | Denali Therapeutics | Series B | 130M |
| 9/2007 | Limerick BioPharma | Debt Financing | 5M |
| 1/2000 | Classmates.com | Series B | 11M |
| 12/2020 | Sesh | Seed Round | 3.5M |
| 1/2016 | Petra Pharma | Series A | 48M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 9/2000 | Viathan Corporation | Venture Round | 17M |
| 6/2000 | ePolicy | Series B | 0 |
| 8/2013 | 908 Devices | Series B | 7M |
| 8/2022 | Happy Health | Series A | 60M |
| 6/2007 | Sapphire Energy | Series A | 1M |
| 10/2015 | Ultivue | Series A | 5.2M |
| 4/2022 | Proof Diagnostics | Series A | 45M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 4/2023 | Recuro Health | Series B | 0 |
| 3/2023 | Rapport Therapeutics | Series A | 0 |
| 3/2023 | Volastra Therapeutics | Series A | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 2/2023 | Aera Therapeutics | Series B | 0 |
| 2/2023 | Aera Therapeutics | Series A | - |
| 2/2023 | IngredientWerks | Seed Round | - |
| 2/2023 | Slingshot Biosciences | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
